10x Genomics, Inc.
NASDAQ10x Genomics enters the post-earnings week with an unusual tension: short sellers are quietly rebuilding positions into a stock that just rocketed 22% in a single week, while analysts race to lift targets that the price has already blown through. The short-covering story that defined the previous note has reversed in the past 48 hours. Short interest jumped 7% in a single session on…
TXG short interest fell 21% over one week to 15.3% of free float, reversing the cover momentum seen just days earlier as stock rallies past analyst targets.
10x Genomics enters the post-earnings week with an unusual tension: short sellers are quietly rebuilding positions into a stock that just rocketed 22% in a single week, while analysts race to lift targets that the…
10x Genomics is having its best month in years — up 38% in July alone — and the shorts are running for the exits. The most striking development this week is the speed of the short-interest unwind. Short interest has…
Snapshot as of 16 Sept 2026
10x Genomics has flipped the script in one week — the stock is up 21% to $45.79, shorts are actively covering, and the rally has now blown past every analyst price target on the Street. The most striking development is…
10x Genomics sits in a rare and uncomfortable spot — the Street is rushing to lift price targets while short interest continues to grind higher, and the stock fell 5.4% on Tuesday to $37.83, still below where most of…
10x Genomics closed June with its stock up 20% on the week and 35% on the month — yet the short base expanded sharply into that rally, the CEO sold stock three times in eight days, and options turned their most bullish…
10x Genomics enters the final week of June with a Barclays target raise landing just as options positioning hits its most bullish extreme of the past year — a confluence that sharpens the tension between a still-heavy…
10x Genomics heads into mid-June with a striking contrast: short sellers are quietly reducing positions into a 50% monthly price rally, while the options market is turning increasingly bullish — a combination that…
10x Genomics reports Q1 2026 results today carrying a notable short position that has been quietly unwinding — and analysts who have spent the past month lifting their targets ahead of the print. Short interest at…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TXG — free to start on ORTEX.
Sign up for free →Open TXG on ORTEX